Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.70 |
| ▸ | RAB9A | P51151 | 9/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | PKM | P14618 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | VDR | P11473 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
| ▸ | AHR | P35869 | 1/20 | 0.67 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.67 |
| ▸ | RELA | Q04206 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830598 | 1.00 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL179157 | 0.88 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL19876187 | 0.88 | ALDH1A1 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16147181 | 0.88 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3417301 | 0.84 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23758270 | 0.83 | AURKA (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL23736199 | 0.83 | TP53 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL31679074 | 0.83 | TP53 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL31154259 | 0.83 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2242715 | 0.83 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403128-B2 | Compositions and methods for blocking sodium channels | Univerity of Virginia Patent Foundation (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-12186317-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2025-01-07 | — | — | US | disclosed |
| WO-2024137505-A2 | METHOD OF IMPROVING CELL FITNESS IN AN EX-VIVO CELL POPULATION | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | US | disclosed |
| US-20220354848-A9 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S.R.L. (IT) | 2022-11-10 | — | — | US | disclosed |
| EP-3526199-B1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354848-A9 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | NPC1 2123/4885RAB9A 3532/4885SMN1; SMN2 1791/4885 |
| US-12403128-B2 | Compositions and methods for blocking sodium channels | SCN3A, SCN1B, SCN2B | NPC1 483/4885RAB9A 2068/4885SMN1; SMN2 228/4885 |
| US-12186317-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | ACMSD, GLS, ALDH7A1 | NPC1 2123/4885RAB9A 3532/4885SMN1; SMN2 1791/4885 |
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | NPC1 989/4885RAB9A 2214/4885SMN1; SMN2 39/4885 |
| US-20230381177-A1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | ACMSD, GLS, ALDH7A1 | NPC1 2123/4885RAB9A 3532/4885SMN1; SMN2 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.